BS_7XQRH69M
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 17.115637319316686
- age_years
- 2.038
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.555
- E2F_TARGETS+0.554
- MYC_TARGETS_V1+0.503
- MITOTIC_SPINDLE+0.321
- MYC_TARGETS_V2+0.295
- PANCREAS_BETA_CELLS+0.271
- SPERMATOGENESIS+0.177
- HEDGEHOG_SIGNALING+0.130
- DNA_REPAIR+0.086
- UV_RESPONSE_DN-0.087
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.658
- INTERFERON_GAMMA_RESPONSE-0.562
- TNFA_SIGNALING_VIA_NFKB-0.547
- IL6_JAK_STAT3_SIGNALING-0.532
- INFLAMMATORY_RESPONSE-0.511
- ALLOGRAFT_REJECTION-0.445
- NOTCH_SIGNALING-0.445
- IL2_STAT5_SIGNALING-0.407
- CHOLESTEROL_HOMEOSTASIS-0.398
- COMPLEMENT-0.394
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3F5PR9GS | medulloblastoma | — | 0.983 |
| 2 | BS_AMZ70B6F | medulloblastoma | — | 0.970 |
| 3 | BS_AM70R8RG | medulloblastoma | — | 0.970 |
| 4 | BS_NKRYMHEP | medulloblastoma | — | 0.967 |
| 5 | BS_M15PW2N0 | medulloblastoma | — | 0.962 |
| 6 | BS_4PH1MBGR | medulloblastoma | — | 0.960 |
| 7 | BS_FCAKKZ20 | medulloblastoma | — | 0.959 |
| 8 | BS_TYAYZ9ZW | medulloblastoma | — | 0.959 |
| 9 | BS_45J79YTF | high-grade glioma | — | 0.959 |
| 10 | BS_YEB88D32 | medulloblastoma | — | 0.957 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.555 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.554 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.503 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.321 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.295 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.271 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.177 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.086 | Idelalisib | — uncovered |